| 1 |
35220216 | Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells. | 2022 Mar |
1 |
| 2 |
33472956 | Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. | 2021 Jan 20 |
2 |
| 3 |
33536335 | SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors. | 2021 Feb 9 |
1 |
| 4 |
33987368 | Metastasis-associated gene 1 (MTA1) enhances cisplatin resistance of malignant pleural mesothelioma by ATR-Chk1-mediated DNA repair. | 2021 Apr |
3 |
| 5 |
34134962 | [Development and functional validation of a nano-delivery system of miR-16/polypeptide targeting ovarian cancer cells]. | 2021 May 20 |
1 |
| 6 |
34474677 | CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer. | 2021 Sep 3 |
1 |
| 7 |
34719665 | Identification of Potential Prognostic and Predictive Biomarkers for Immune-Checkpoint Inhibitor Response in Small Cell Lung Cancer. | 2021 Nov 1 |
1 |
| 8 |
31782150 | Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient-derived osteosarcoma cells and synergizes with cisplatin and talazoparib. | 2020 Aug 15 |
1 |
| 9 |
32371584 | CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma. | 2020 Jun |
1 |
| 10 |
32610557 | Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts. | 2020 Jun 29 |
1 |
| 11 |
33216839 | Evidence for functional and regulatory cross-talk between Wnt/β-catenin signalling and Mre11-Rad50-Nbs1 complex in the repair of cisplatin-induced DNA cross-links. | 2020 Nov 3 |
1 |
| 12 |
33261142 | Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer. | 2020 Nov 27 |
2 |
| 13 |
30665195 | Tissue-Specific Chk1 Activation Determines Apoptosis by Regulating the Balance of p53 and p21. | 2019 Feb 22 |
1 |
| 14 |
30771522 | Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death. | 2019 Jun |
7 |
| 15 |
31061066 | Targeting the High-Mobility Group Box 3 Protein Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin. | 2019 Jul 1 |
6 |
| 16 |
31078449 | FANCM, RAD1, CHEK1 and TP53I3 act as BRCA-like tumor suppressors and are mutated in hereditary ovarian cancer. | 2019 Jun |
2 |
| 17 |
31140586 | Fbxo6 confers drug-sensitization to cisplatin via inhibiting the activation of Chk1 in non-small cell lung cancer. | 2019 Jul |
2 |
| 18 |
31441116 | Withaferin A inhibits expression of ataxia telangiectasia and Rad3-related kinase and enhances sensitivity of human breast cancer cells to cisplatin. | 2019 Nov |
1 |
| 19 |
31528122 | Long non-coding RNA LINC00485 acts as a microRNA-195 sponge to regulate the chemotherapy sensitivity of lung adenocarcinoma cells to cisplatin by regulating CHEK1. | 2019 |
1 |
| 20 |
31839711 | VE-822 mediated inhibition of ATR signaling sensitizes chondrosarcoma to cisplatin via reversion of the DNA damage response. | 2019 |
5 |
| 21 |
29704517 | DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer. | 2018 Aug 1 |
4 |
| 22 |
29890208 | The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma. | 2018 Sep 28 |
1 |
| 23 |
30145203 | Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target. | 2018 Nov 28 |
1 |
| 24 |
30260263 | RNF138 confers cisplatin resistance in gastric cancer cells via activating Chk1 signaling pathway. | 2018 |
2 |
| 25 |
28262781 | WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance. | 2017 Mar 6 |
2 |
| 26 |
28291626 | Mus81 knockdown sensitizes colon cancer cells to chemotherapeutic drugs by activating CHK1 pathway. | 2017 Oct |
3 |
| 27 |
28454371 | Synergistic effects of a novel lipid-soluble extract from Pinellia pedatisecta Schott and cisplatin on human cervical carcinoma cell lines through the regulation of DNA damage response signaling pathway. | 2017 Apr |
1 |
| 28 |
28490518 | CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. | 2017 Jul 15 |
1 |
| 29 |
28888100 | Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells. | 2017 Oct |
1 |
| 30 |
26657501 | ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer. | 2016 Jan 12 |
4 |
| 31 |
27163202 | Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest. | 2016 Jun |
7 |
| 32 |
27191498 | Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells. | 2016 Jul 5 |
1 |
| 33 |
27246979 | Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells. | 2016 Jun 28 |
2 |
| 34 |
27664008 | Dietary flavonoid derivatives enhance chemotherapeutic effect by inhibiting the DNA damage response pathway. | 2016 Nov 15 |
1 |
| 35 |
25593194 | Screening analysis of ubiquitin ligases reveals G2E3 as a potential target for chemosensitizing cancer cells. | 2015 Jan 20 |
2 |
| 36 |
25774168 | Targeting lung cancer through inhibition of checkpoint kinases. | 2015 |
1 |
| 37 |
26161259 | Triptolide potentiates lung cancer cells to cisplatin-induced apoptosis by selectively inhibiting the NER activity. | 2015 |
1 |
| 38 |
26313152 | IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules. | 2015 Sep 29 |
1 |
| 39 |
24218165 | Cisplatin associated with LY294002 increases cytotoxicity and induces changes in transcript profiles of glioblastoma cells. | 2014 Jan |
1 |
| 40 |
24362713 | Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary. | 2014 Jan |
1 |
| 41 |
24853623 | Co-abrogation of Chk1 and Chk2 by potent oncolytic adenovirus potentiates the antitumor efficacy of cisplatin or irradiation. | 2014 May |
1 |
| 42 |
23275151 | PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. | 2013 Apr |
1 |
| 43 |
23548269 | ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. | 2013 Jun 15 |
1 |
| 44 |
23839309 | Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. | 2013 Sep |
1 |
| 45 |
21927021 | The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. | 2012 Apr 26 |
5 |
| 46 |
22537224 | Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. | 2012 Apr 26 |
4 |
| 47 |
22585575 | CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. | 2012 Jun |
2 |
| 48 |
22743332 | BRCA1-dependent Chk1 phosphorylation triggers partial chromatin disassociation of phosphorylated Chk1 and facilitates S-phase cell cycle arrest. | 2012 Nov |
1 |
| 49 |
22942255 | Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. | 2012 Nov 15 |
3 |
| 50 |
22957056 | Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells. | 2012 |
1 |